according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Alendronate / Vitamin D Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H302: Harmful if swallowed. Skin irritation, Category 2 H315: Causes skin irritation.

Serious eye damage, Category 1 H318: Causes serious eye damage.

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child.

Specific target organ toxicity - single ex- H335: May cause respiratory irritation.

posure, Category 3

Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms





according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 6.0
 06.04.2024
 22059-00023
 Date of first issue: 15.10.2014

Signal word : Danger

Hazard statements : H302 Harmful if swallowed.

H315 Causes skin irritation.

H318 Causes serious eye damage.H335 May cause respiratory irritation.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh

air and keep comfortable for breathing. Call a POISON

CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a

POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Alendronate

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
---------------	---------	----------------	---------------

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Registration number	= 20 - < 30
Repr. 2; H361d STOT SE 3; H335 STOT RE 2; H373 (Bone, Stomach, Kidney)	
	= 0,025 - < 0,1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention immediately.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Causes skin irritation.

Causes serious eye damage. May cause respiratory irritation.

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 6.0
 06.04.2024
 22059-00023
 Date of first issue: 15.10.2014

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx) Phosphorus compounds

Metal oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering

over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Dust 5 mg/m3

Value type (Form of exposure): TWA (respirable dust)

Basis: FOR-2011-12-06-1358

10 mg/m3

Value type (Form of exposure): TWA (total dust)

Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Alendronate	121268-17- 5	TWA	20 μg/m3 (OEB 3)	Internal
		Wipe limit	200 μg/100 cm ²	Internal
Colecalciferol	67-97-0	TWA	5 μg/m3 (OEB 4)	Internal
		Wipe limit	50 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : off-white

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n- : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

octanol/water

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1.965 mg/kg

Method: Calculation method

Components:

Alendronate:

Acute oral toxicity : LD50 (Rat): 552 - 626 mg/kg

LD50 (Mouse): 966 - 1.280 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Colecalciferol:

Acute oral toxicity : LD50 (Rat, male): 35 mg/kg

Acute inhalation toxicity : Acute toxicity estimate: 0,05 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Expert judgement

Acute dermal toxicity : Acute toxicity estimate: 50 mg/kg

Method: Expert judgement

Skin corrosion/irritation

Causes skin irritation.

Components:

Alendronate:

Species : Rabbit

Remarks : Severe skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Alendronate:

Species : Rabbit

Result : Severe irritation

Colecalciferol:

Species : Rabbit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Alendronate:

Remarks : No data available

Colecalciferol:

Test Type : Maurer optimisation test

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Alendronate:

Genotoxicity in vitro : Test Type: Alkaline elution assay

Test system: rat hepatocytes

Result: negative

Test Type: Bacterial reverse mutation assay (AMES) Metabolic activation: with and without metabolic activation

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: equivocal

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse Result: negative

Colecalciferol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: equivocal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 474

Result: negative

Test Type: In vivo mammalian alkaline comet assay

Species: Rat

Application Route: Ingestion

Result: positive

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Alendronate:

Species : Rat, male
Application Route : Oral
Exposure time : 2 Years

1 mg/kg body weight3,75 mg/kg body weight

Target Organs : Thyroid

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Alendronate:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 5 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development Species: Rat, female

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Application Route: Oral

Developmental Toxicity: LOAEL: 1 - 15 mg/kg body weight Symptoms: Reduced number of viable fetuses, Reduced body

weight, Skeletal malformations

Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Development Species: Rabbit, female Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight

Result: No adverse effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

May cause respiratory irritation.

Components:

Alendronate:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Alendronate:

Target Organs : Bone, Stomach, Kidney

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Colecalciferol:

Exposure routes : Ingestion

Target Organs : Kidney, Blood, Bone

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Alendronate:

Species: RatNOAEL: 2,5 mg/kgLOAEL: > 2,5 mg/kgApplication Route: IntravenousExposure time: 53 WeeksTarget Organs: Stomach

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 6.0
 06.04.2024
 22059-00023
 Date of first issue: 15.10.2014

Species : Dog

LOAEL : 0,01 mg/kg
Application Route : Intravenous

Exposure time : 3 yr

Target Organs : Stomach, Bone, Kidney

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 4 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Kidney

Colecalciferol:

Species : Rat

NOAEL : 0,06 mg/kg
LOAEL : 0,3 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Method : OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

Components:

Alendronate:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Alendronate:

Inhalation : Symptoms: respiratory tract irritation
Skin contact : Symptoms: Severe irritation, skin blistering

Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: Gastrointestinal disturbance, musculoskeletal pain

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

SECTION 12: Ecological information

12.1 Toxicity

Components:

Alendronate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 27 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 1.000 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 170 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 10

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC: 1,1 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

LOEC: 1,9 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 4,7 mg/l

Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Colecalciferol:

Toxicity to fish : LL50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other:

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

EL50 (Scenedesmus capricornutum (fresh water algae)): > Toxicity to algae/aquatic plants

100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

12.2 Persistence and degradability

Components:

Alendronate:

Result: Readily biodegradable. Biodegradability

Biodegradation: 70,3 % Exposure time: 7 d

Stability in water Degradation half life (DT50): 375 d

Method: OECD Test Guideline 111

Colecalciferol:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: <= 7 % Exposure time: 28 d

Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

Alendronate:

Partition coefficient: n-

octanol/water

: log Pow: -1,73

Colecalciferol:

Partition coefficient: n-

octanol/water

: $\log Pow: > 6.2$

Method: OECD Test Guideline 107

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment This substance/mixture contains no components considered

> to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

The substance/mixture does not contain components consid-Assessment

ered to have endocrine disrupting properties according to

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 06.04.2024 22059-00023 Date of first issue: 15.10.2014 6.0

> REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Empty containers should be taken to an approved waste han-Contaminated packaging

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN Not regulated as a dangerous good **ADR** Not regulated as a dangerous good RID Not regulated as a dangerous good **IMDG** Not regulated as a dangerous good **IATA** Not regulated as a dangerous good

14.2 UN proper shipping name

ADN Not regulated as a dangerous good **ADR** Not regulated as a dangerous good RID Not regulated as a dangerous good **IMDG** Not regulated as a dangerous good **IATA** Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN Not regulated as a dangerous good **ADR** Not regulated as a dangerous good RID Not regulated as a dangerous good **IMDG** Not regulated as a dangerous good IATA Not regulated as a dangerous good

14.4 Packing group

ADN Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 75

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not

If you intend to use this product as tattoo ink, please contact your vendor.

dor.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Not applicable

REACH - List of substances subject to authorisation

(Annex XIV)

Not applicable

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Not applicable

Regulation (EU) 2019/1021 on persistent organic pollu-

Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

Not applicable

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H300 : Fatal if swallowed.
H302 : Harmful if swallowed.
H310 : Fatal in contact with skin.
H315 : Causes skin irritation.

H318 : Causes serious eye damage.

H330 : Fatal if inhaled.

H335 : May cause respiratory irritation.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H373 : May cause damage to organs through prolonged or repeated

exposure.

H413 : May cause long lasting harmful effects to aquatic life.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage Repr. : Reproductive toxicity

Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Acute Tox. 4	H302	Calculation method
Skin Irrit. 2	H315	Calculation method
Eye Dam. 1	H318	Calculation method
Repr. 2	H361d	Calculation method
STOT SE 3	H335	Calculation method
STOT RE 2	H373	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alendronate / Vitamin D Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 6.0 06.04.2024 22059-00023 Date of first issue: 15.10.2014

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN